LV14963A - Endoteliālās disfunkcijas korektors - Google Patents

Endoteliālās disfunkcijas korektors

Info

Publication number
LV14963A
LV14963A LV130088A LV130088A LV14963A LV 14963 A LV14963 A LV 14963A LV 130088 A LV130088 A LV 130088A LV 130088 A LV130088 A LV 130088A LV 14963 A LV14963 A LV 14963A
Authority
LV
Latvia
Prior art keywords
corrector
endothelial dysfunction
meldonium
hmg
thrombosis
Prior art date
Application number
LV130088A
Other languages
English (en)
Other versions
LV14963B (lv
Inventor
Ivars KALVIŅŠ
Anatolijs Birmans
Māris VĒVERIS
Original Assignee
Tetra, Sia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetra, Sia filed Critical Tetra, Sia
Priority to LVP-13-88A priority Critical patent/LV14963B/lv
Priority to PCT/LV2014/000006 priority patent/WO2014209092A1/en
Publication of LV14963A publication Critical patent/LV14963A/lv
Publication of LV14963B publication Critical patent/LV14963B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Izveidota sinerģiska terapeitiska kompozīcija, kas ietver meldonija acetilsalicilskābes aditīvo sāli kā endoteliālās disfunkcijas korektoru un HMG-CoA reduktāzes inhibitoru, trombozes profilaksei un/vai ārstēšanai.
LVP-13-88A 2013-06-28 2013-06-28 Endoteliālās disfunkcijas korektors LV14963B (lv)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LVP-13-88A LV14963B (lv) 2013-06-28 2013-06-28 Endoteliālās disfunkcijas korektors
PCT/LV2014/000006 WO2014209092A1 (en) 2013-06-28 2014-06-27 Corrector of endothelial dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-13-88A LV14963B (lv) 2013-06-28 2013-06-28 Endoteliālās disfunkcijas korektors

Publications (2)

Publication Number Publication Date
LV14963A true LV14963A (lv) 2015-03-20
LV14963B LV14963B (lv) 2015-10-20

Family

ID=51352737

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-13-88A LV14963B (lv) 2013-06-28 2013-06-28 Endoteliālās disfunkcijas korektors

Country Status (2)

Country Link
LV (1) LV14963B (lv)
WO (1) WO2014209092A1 (lv)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1095695A (en) 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
JP2001500875A (ja) 1996-09-18 2001-01-23 メルク エンド カンパニー インコーポレーテッド 心臓血管系疾患関連の危険性を減らす併用治療法
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol
US6596708B1 (en) 2001-09-07 2003-07-22 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
EP1865945A4 (en) 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
US7598233B2 (en) * 2005-03-28 2009-10-06 Kowa Co., Ltd. Method for treating thrombosis
DE102005025283A1 (de) 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
DE102005049293A1 (de) 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
WO2009022821A2 (en) 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
RU2364392C1 (ru) 2008-03-19 2009-08-20 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции ацетилсалициловой кислотой при l-name индуцированном дефиците оксида азота
CN102802618B (zh) * 2009-06-25 2014-06-18 泰特拉有限公司 烟酸和米曲肼的治疗组合
KR20120050437A (ko) 2009-06-25 2012-05-18 테트라, 시아 신규한 아세틸살리실산 염들
US20110275649A1 (en) 2010-05-05 2011-11-10 Palmetto Pharmaceuticals Llc Combination therapy for the prevention of statin induced diabetes
KR20120068277A (ko) 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors

Also Published As

Publication number Publication date
WO2014209092A1 (en) 2014-12-31
LV14963B (lv) 2015-10-20

Similar Documents

Publication Publication Date Title
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
IN2014DN10670A (lv)
MX2015015416A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX2019005831A (es) Aptameros para usarse en la inhibicion y/o supresion de la activacion de tlr9.
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX348397B (es) Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico.
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
PH12015502706B1 (en) Oral formulation for the treatment of cardiovascular diseases
IN2014DN08443A (lv)
GB201112145D0 (en) Means and methods for the treatment of pathological angiogenesis
MX2016006240A (es) Administración de metales pesados para la inhibición de la corrosión de concreto inducida por microbios.
TN2015000021A1 (en) Use of vegfr-3 inhibitors for treating hepatocellular carcinoma
LV14963A (lv) Endoteliālās disfunkcijas korektors
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
MX2015016093A (es) Trans-clomifeno y sus analogos como agentes que aumentan la densidad mineral osea.